Did You Know...
...During the Civil War, the Confederacy established its own Patent Office which issued 266 patents, a third of which concerned implements of war.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8142784 | Antibody-drug conjugates and methods The present invention relates to antibody-drug conjugate compounds of Formula I: Ab-(L-D)p I where one or more maytansinoid drug moieties (D) are covalently linked by L to an antibody (Ab) which binds to a... | 03/27/2012 |
| 8088387 | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates The present invention discloses a method for targeting maytansinoids to a selected cell population, the method comprising contacting a cell population or tissue suspected of containing the selected cell population with a cell-binding agent maytansinoid conjugate, wh... | 01/03/2012 |
| 8067007 | Compositions and methods for identifying and targeting cancer cells of alimentary canal origin Screening and diagnostic reagents, kits and methods for primary and/or metastatic stomach or esophageal cancer are disclosed. Compositions for and methods of imaging and treating primary and/or metastatic stomach or esophageal cancer are disclosed. Vaccines composit... | 11/29/2011 |
| 8034787 | Enzyme-cleavable prodrug compounds The prodrug of the invention is a modified form of a therapeutic agent and comprises a therapeutic agent, an oligopeptide, a stabilizing group and, optionally, a linker group. The prodrug is cleavable by the enzyme Thimet oligopeptidase, or TOP. Also disclosed are m... | 10/11/2011 |
| 7854933 | Compositions and methods for identifying and targeting cancer cells of alimentary canal origin Screening and diagnostic reagents, kits and methods for primary and/or metastatic stomach or esophageal cancer are disclosed. Compositions for and methods of imaging and treating primary and/or metastatic stomach or esophageal cancer are disclosed. Vaccines composit... | 12/21/2010 |
| 7767208 | Noninvasive vascular therapy The present invention is drawn to methods and compounds for transcutaneous photodynamic therapy (“PDT”) of a target tissue or compositions in a mammalian subject, which includes administering to the subject a therapeutically effective amount of a photosensitizin... | 08/03/2010 |
| 7709000 | Antibody recognizing a small subset of human hematopoietic cells The subject invention pertains to antibodies that have binding specificity for an antigen that is expressed on a subset of human, hematopoietic mononuclear cells, including a hematopoietic stem cell population, but is not expressed on normal, mature myeloid cells. I... | 05/04/2010 |
| 7666425 | Treatment and diagnosis of prostate cancer The present invention is directed to the use of antibodies or binding portions thereof, probes, ligands, or other biological agents which either recognize an extracellular domain of prostate specific membrane antigen or bind to and are internalized with prostate spe... | 02/23/2010 |
| 7655234 | Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer A gene (designated 161P2F10B) and its encoded protein are described wherein 161P2F10B exhibits tissue specific expression in normal adult tissue, it is aberrantly expressed in the cancers listed in Table I. Consequently, 161P2F10B provides a diagnostic, prognostic, ... | 02/02/2010 |
| 7585505 | Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer A gene (designated 161P2F10B) and its encoded protein are described wherein 161P2F10B exhibits tissue specific expression in normal adult tissue, it is aberrantly expressed in the cancers listed in Table I. Consequently, 161P2F10B provides a diagnostic, prognostic, ... | 09/08/2009 |
| 7498035 | Compounds of hydrophilic polymer-polycarboxyl oligopeptide and medicines, medical composite comprising above compound and use of above compound in medicines The present invention relates to a conjugate of hydrophilic polymer-multicarboxyl oligopeptide and drug molecule of the following formula: wherein: P is a hydrophilic polymer; m is an integer of 2˜12; j is an integer of 1... | 03/03/2009 |
| 7498034 | Imaging, diagnosis and treatment of disease The present invention relates to endothelial cell-specific genes and encoded polypeptides and materials and uses thereof in the imaging, diagnosis and treatment of conditions involving the vascu lar endothelium. ... | 03/03/2009 |
| 7429645 | Humanized anti-lymphotoxin beta receptor antibodies This invention concerns humanized antibodies specific for the lymphotoxin beta receptor (LT-β-R), cell lines that produce these antibodies, immunochemicals made from the antibodies, and diagnostic methods that use the antibodies. The invention also relates to the u... | 09/30/2008 |
| 7429382 | Antibodies that bind cell-associated CA 125/O772P and methods of use thereof The present invention provides antibodies, and antigen-binding fragments of antibodies, fusion polypeptides and analogs that preferentially bind cell-associated CA 125/O772P polypeptides relative to shed CA 125/O772P polypeptides. The present invention further provi... | 09/30/2008 |
| 7425328 | Tissue factor antibodies and uses thereof The present invention provides antibodies capable of binding to human tissue factor, which do not inhibit tissue factor mediated blood coagulation compared to a normal plasma control. Further described are methods of making and methods of using the antibodies of the... | 09/16/2008 |
| 7413739 | Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds The invention features polymeric biomaterials formed by nucleophilic addition reactions to conjugated unsaturated groups. These biomaterials may be used for medical treatments. ... | 08/19/2008 |
| 7413738 | Releasable polymeric conjugates based on biodegradable linkers Activated polymeric bicine derivatives such as, as well as conjugates made therewith are disclosed. Methods of making and using the bicine derivatives are also disclosed. ... | 08/19/2008 |
| 7407656 | PSCA: prostate stem cell antigen and uses thereof The invention provides a novel prostate cell-surface antigen, designated Prostate Stem Cell Antigen (PSCA), which is widely over-expressed across all stages of prostate cancer, including high grade prostatic intraepithelial neoplasia (PIN), androgen-dependent and an... | 08/05/2008 |
| 7393531 | Cytotoxicity mediation of cells evidencing surface expression of MCSP This invention relates to the diagnosis and treatment of cancerous diseases, particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more ... | 07/01/2008 |
| 7387772 | Chimeric, human and humanized anti-CSAP monoclonal antibodies The present invention provides humanized, chimeric and human anti-CSAp antibodies and anti-CSAp antibody fusion proteins that are useful for the treatment and diagnosis of various cancers, including colon cancer. ... | 06/17/2008 |
| 7381407 | Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen The present invention relates to monoclonal antibodies that bind to the extracellular domain of prostate-specific membrane antigen (PSMA), hybridoma cell lines producing the antibodies, and methods of using such antibodies for diagnosis and treatment of cancer. In p... | 06/03/2008 |
| 7378091 | Antibodies against carbonic anhydrase IX (CA IX) tumor antigen The present invention relates generally to the generation and characterization of anti-CA IX monoclonal antibodies. The invention further relates to the use of such anti-CA IX antibodies in the diagnosis and treatment of disorders associated with increased activity ... | 05/27/2008 |
| 7371723 | Therapeutic agents comprising pro-apoptotic proteins The present invention relates to targeted killing of a cell utilizing a chimeric polypeptide comprising a cell-specific targeting moiety and a signal transduction pathway factor. In a preferred embodiment, the signal transduction pathway factor is an apoptosis-induc... | 05/13/2008 |
| 7368565 | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents The present invention discloses a one-step process for the production of cytotoxic conjugates of maytansinoids and cell binding agents. Maytansinoids having a disulfide linker that bears a reactive moiety are linked to cell binding agents, such as antibodies, withou... | 05/06/2008 |
| 7368542 | Method of altering the binding specificity of plasma proteins by oxidation-reduction reactions The binding specificity of at least one plasma protein suspended or dissolved in a liquid medium is altered by exposing the protein to an oxidizing agent or an electric current sufficient to alter its binding specificity. A masked protein such as an autoantibody can... | 05/06/2008 |
| 7361342 | Cancerous disease modifying antibodies The present invention relates to a method for producing patient cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the produ... | 04/22/2008 |
| 7361347 | Cytotoxic CD44 antibody immunoconjugates The invention relates to novel conjugates of CD44 antibodies with cytotoxic compounds, pharmaceutical compositions comprising such compounds, and their use in tumor therapy. ... | 04/22/2008 |
| 7361336 | Methods of cancer therapy targeted against a cancer stem line Improved methods for treatment of cancer which involve the targeting of slow-growing, relatively mutationally-spared cancer stem line are provided. These methods are an improvement over previous cancer therapeutic methods because they provide for very early cancer t... | 04/22/2008 |
| 7361343 | Cytotoxicity mediation of cells evidencing surface expression of CD63 This invention relates to the diagnosis and treatment of cancerous diseases, particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more ... | 04/22/2008 |
| 7339033 | PRO1481 The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of ... | 03/04/2008 |
| 7332164 | Heterobifunctional polymeric bioconjugates Heterobifunctional polymeric prodrug platforms for delivering biologically active compounds, including proteins, monoclonal antibodies and the like are disclosed. One preferred compound is Methods of making and u... | 02/19/2008 |
| 7319139 | TAG-72 specific C2 domain deleted antibodies Methods, compositions and kits comprising dimeric antibodies for the treatment of neoplastic, autoimmune or other disorders are provided. The dimeric antibodies of the instant invention may comprise two antibody molecules (H4L4) having the same... | 01/15/2008 |
| 7318924 | Antibodies against cancer An isolated binding partner of a Cripto-1 protein, Pim-1 protein or an antigen present in a colon cancer cell lysate is described. The binding partner inhibits growth of one or more cancer cell types and may be used in an anti-cancer agent for treating cancer in a s... | 01/15/2008 |
| 7314862 | Antitumor agent The present invention relates to an antitumor agent containing a histone deacetylase inhibitor and a topoisomerase II inhibitor in combination. This combination has been found to exhibit a synergistic anticancer or antitumor effect compared to administration of eith... | 01/01/2008 |
| 7311892 | Multidrug multiligand conjugates for targeted drug delivery Described is a multi drug multiligand conjugate for targeted drug delivery. The MDML conjugate contains a plurality of tripartite molecules linked to a central scaffold moiety, with each tripartite molecule comprising a targeting molecule, a therapeutic agent and a ... | 12/25/2007 |
| 7307154 | DNA encoding a novel RG1 polypeptide The present invention relates to novel human extracellular matrix polypeptides, designated RG1, polynucleotides encoding the polypeptides, methods for producing the polypeptides, expression vectors and genetically engineered host cells for expression of the polypept... | 12/11/2007 |
| 7303749 | Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents The present invention is based on the discovery that the administration of at least one immunoconjugate and at least one chemotherapeutic agent provides an unexpectedly superior treatment for cancer. The present invention is directed to compositions comprising at le... | 12/04/2007 |
| 7291673 | Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds The invention features polymeric biomaterials formed by nucleophilic addition reactions to conjugated unsaturated groups. These biomaterials may be used for medical treatments. ... | 11/06/2007 |
| 7285269 | Antibodies directed to tumor necrosis factor Antibodies directed to the antigen TNFα and uses of such antibodies. In particular, fully human monoclonal antibodies directed to the antigen TNFα. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, ... | 10/23/2007 |
| 7285635 | Modified proteins, designer toxins, and methods of making thereof The present invention concerns methods of reducing the antigenicity of a proteinaceous compound while maintaining the compounds biological activity, as well as proteinaceous compositions with biological activity but reduced antigenicity. These methods and compositio... | 10/23/2007 |
